亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

醋酸氫化可的松50-03-3

 
 
單價 面議對比
詢價 暫無
發(fā)貨 湖北武漢市付款后3天內(nèi)
庫存 100公斤起訂0.5公斤
品牌 本廠
型號 50-03-3
規(guī)格 99
過期 長期有效
更新 2012-02-28 11:55
 

武漢鮮保生物技術(shù)有限公司

企業(yè)會員第14年
資料未認證
保證金未繳納
詳細說明

醋酸氫化可的松
英 文 名:Hydrocortisone acetate
化 學 名:11β,17-二羥基-3,20-二酮孕甾-4-烯-2l-醋酸酯
類    別:腎上腺皮質(zhì)激素類原料藥
規(guī)    格:1Kg/聽、5Kg/聽
標    準:CP/BP/USP/EP
性    狀:本品為白色或類白色的結(jié)晶性粉末;無臭。
鑒    別:呈陽性反應
 cas:50-03-3
1.適應癥
  主要用于治療類風濕性關(guān)節(jié)炎、風濕熱、痛風、支氣管哮喘等。針劑用于結(jié)核性或化膿性腦膜炎、結(jié)核性胸膜炎、膿胸、關(guān)節(jié)炎、腱鞘炎、肌腱勞損、扭傷、結(jié)節(jié)性癢疹、扁平苔蘚等。滴眼劑用于各種眼炎。霜劑用于過敏性或脂溢性皮炎、瘙癢癥等。
2.注意事項
  長期較大劑量應用皮質(zhì)類激素藥物,可引起醫(yī)源性腎上腺皮質(zhì)功能亢進癥(類柯興綜合征),表現(xiàn)為滿月臉、水牛背、向心性肥胖、皮膚菲薄而有紫紋、肌肉萎縮無力、骨質(zhì)疏松、高血糖、糖尿、高血壓、低血鉀、女性男性化如多毛等其他情況
 

舉報收藏 0評論 0
更多>本企業(yè)其它產(chǎn)品
倍他米松二丙酸酯5593-20-4 曲安奈德Triamcinolone acetonide 地塞米松磷酸鈉 醋酸地塞米松 倍他米松378-44-9 地塞米松50-02-2 銷售氫化可的松50-23-7
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |